Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

Conditions:   SARS-CoV;   SARS-CoV-2 Interventions:   Biological: VXCO-100;   Biological: COVID-19 mRNA vaccine and VXCO-100;   Biological: COVID-19 mRNA vaccine Sponsor:   Vaccine Company, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials